LIPEDEMA

The Biology of Lipedema

Modern science confirms what patients have long known: adipose tissue in lipedema is biologically different.

Lipedema is not simply excess body weight. Adipose tissue in affected areas differs significantly both from healthy adipose tissue and from adipose tissue in conventional obesity. These biological differences explain why lipedema adipose tissue behaves differently and why conventional weight-loss approaches have little effect on the condition.

Modern research has shown that fat cells (adipocytes) in lipedema are enlarged, surrounded by altered, firmer connective tissue and interwoven with abnormally structured blood vessels. They are also surrounded by a distinct immune environment that further limits the normal processes of fat breakdown.

Key biological features of lipedema:

› enlarged fat cells (adipocytes) and altered, firmer connective tissue (fibrosis) surrounding them
› altered microvasculature, leading to more rapid bruising and swelling
› a distinct anti-inflammatory immune profile that differs substantially from obesity
› more than 4,000 differentially expressed genes compared with healthy adipose tissue
› increased tissue sensitivity and altered pain perception
› impaired lymphatic flow in advanced stages of the condition

In lipedema, adipocytes in the affected areas become markedly enlarged (adipocyte hypertrophy), while collagen gradually accumulates in the surrounding connective tissue. This results in progressive fibrosis—hardening and structural remodelling of adipose tissue—that has a significant impact on the course of the condition.

Modern genetic studies have identified more than 4,000 differentially expressed genes in lipedema adipose tissue compared with healthy adipose tissue. These genes influence fat metabolism, cell growth and the structure of connective tissue, which provides support and structure to adipose tissue.

This progressive fibrosis is responsible for the characteristic firm, nodular or granular texture of adipose tissue in lipedema, which can be recognised during a clinical examination. Because of its altered structure, the tissue also becomes substantially less responsive to the usual processes of fat breakdown.

Lipedema adipose tissue is also accompanied by structural changes in the microvasculature (microangiopathy). These include increased capillary fragility and permeability, an impaired protective layer of the vessel walls, and elevated levels of growth factors that affect the growth and function of the vascular and lymphatic systems.

These changes contribute significantly to some of the most characteristic symptoms of lipedema: frequent and rapid bruising, swelling that worsens in warm conditions or after prolonged standing, and a sensation of heaviness and tightness in the legs.

One of the most important recent findings in lipedema research is that its immune profile differs substantially from that of obesity. In obesity, inflammatory immune cells (M1 macrophages) predominate in adipose tissue, whereas in lipedema other immune cells (anti-inflammatory M2 macrophages) predominate. This important difference was confirmed by a study published in 2025 in Biomedicines. The finding has important clinical implications: it helps explain why adipose tissue in lipedema does not respond to the same treatment approaches as adipose tissue in obesity, while also opening up new possibilities for targeted therapies.

Lipedema is primarily a disease of adipose tissue, but as it progresses it can gradually affect the lymphatic system.

In the early stages, lymphatic function is largely preserved. In more advanced forms, however, increased adipose tissue and progressive fibrosis can impede normal lymphatic flow. This causes additional accumulation of interstitial fluid in the subcutaneous tissue and swelling, and may also lead to the development of lipolymphedema.

Understanding this distinction is clinically very important when differentiating lipedema from lymphedema: in lipedema, the underlying problem is pathologically altered adipose tissue, while lymphatic complications develop secondarily. This is why treatment must be holistic, individualised and tailored to the stage of the condition.

Pain is one of the most common and characteristic symptoms of lipedema, but it was long believed to arise mainly from increased tissue volume or swelling. More recent research indicates that lipedema also involves changes in nervous-system function and pain perception.

Studies have shown that women with lipedema often have increased sensitivity to painful stimuli. For some, pain may occur even with light touch or pressure that would not normally cause discomfort in healthy individuals. Researchers have also identified changes in sensory processing and signs of neuroinflammatory processes that may contribute to the onset and persistence of pain.

These findings confirm that pain in lipedema is part of the condition itself, rather than simply a consequence of increased adipose tissue, swelling or psychological burden. They also help explain why pain intensity is often disproportionate to visible changes in the body.

Understanding these mechanisms is important for treatment, because effective lipedema care must address not only the volume of affected areas but also appropriate pain management and improved quality of life.